January 2022

Molnupiravir: Enzyme Recycling Information for M4ALL's Two-step Enzymatic Process

Medicines for All


December 2021

Toward a Practical, Nonenzymatic Process for Investigational COVID-19 Antiviral Molnupiravir from Cytidine: Supply-Centered Synthesis.

Vijayagopal Gopalsamuthiram, Appasaheb L. Kadam, Jeffrey K. Noble, David R. Snead, Corshai Williams, Timothy F. Jamison, Chris Senanayake, Ajay K. Yadaw, Sarabindu Roy, Gopal Sirasani, B. Frank Gupton, Justina Burns, Daniel W. Cook, Rodger W. Stringham, Saeed Ahmad, and Rudy Krack


October 2021

Engineering a Cytidine Aminotransferase for Biocatalytic Production of the Covid-19 Antiviral Molnupiravir

Ashleigh J. Burke, William R. Birmingham, Ying Zhuo, Bruna Zucoloto da Costa, Rebecca Crawshaw, Thomas W. Thorpe, Ian Rowles, James Finnigan, Carl Young, Simon J. Charnock, Sarah L. Lovelock, Nicholas J. Turner, and Anthony P. Green


July 2021

Toward a Practical, Two-Step Process for Molnupiravir: Direct Hydroxamination of Cytidine Followed by Selective Esterification

Dinesh J. Paymode, N. Vasudevan, Saeed Ahmad, Appasaheb L. Kadam, Flavio S.P. Cardoso, Justina M. Burns, Daniel W. Cook, Rodger W. Stringham, and David R. Snead


April 2021

Progress Toward a Large-Scale Synthesis of Molnupiravir (MK-4482, EIDD-2801) from Cytidine

Grace P. Ahlqvist, Catherine P. McGeough, Chris Senanayake, Joseph D. Armstrong, Ajay Yadaw, Sarabindu Roy, Saeed Ahmad, David R. Snead, And Timothy F. Jamison


October 2020

A concise route to MK-4482 (EIDD-2801) from cytidine

N. Vasudevan, Grace P. Ahlqvist, Catherine P. McGeough, Dinesh J. Paymode, Flavio S. P. Cardoso, Tobias Lucas, Jule-Phillip Dietz, Till Opatz, Timothy F Jamison, Frank B. Gupton and David R. Snead.


October 2020

A High-Yielding Synthesis of EIDD-2801 from Uridine

Alexander Steiner, Desiree Znidar, Sándor B. Ötvös, David R. Snead, Doris Dallinger, and C. Oliver Kappe


May 29, 2020

An Efficient Synthesis of Tenofovir (PMPA): A Key Intermediate Leading to Tenofovir-Based HIV Medicines

Brenden P. Derstine, John W. Tomlin, Cheryl L. Peck, Jule-Phillip Dietz, Brenden T. Herrera, Flavio S. P. Cardoso, Dinesh J. Paymode, Andrew C. Yue, Anthony J. Arduengo III, Till Opatz, David R. Snead, Rodger W. Stringham, D. Tyler McQuade*, and B. Frank Gupton*


March 2020

Supply Centered Synthesis to Current Late-State Intermediate: (1R,2S,5R)-2-isopropyl-5-methylcyclohexyl 5-hydroxy-1,3-oxathiolane-2-carboxylate

Medicines for All


June 2019

Continuous synthesis of the pyridone in route to dolutegravir

Medicines for All


April 2019

Synthesis of 5-Fluorocytosine Using 2-Cyano-2-fluoroethenolate as a Key Intermediate

Jule-Philipp Dietz, Brenden P. Derstine, Dorota Ferenc, Evan T. Crawford, Anthony J. Arduengo III, B. Frank Gupton, D. Tyler McQuade, and Till Opatz


March 2019

A Holistic Approach to Streamlining Pharmaceutical Processes: A Conversation

B. Frank Gupton and D. Tyler McQuade


January 2019

5-fluorocytosine

Medicines for All


January 2019

Process Design and Optimization for the Continuous Manufacturing of Nevirapine, an Active Pharmaceutical Ingredient for HIV Treatment

Samir Diab, D. Tyler McQuade, B. Frank Gupton, and Dimitrios I. Gerogiorgis


May 2018

7-Step Flow Synthesis of the HIV Integrase Inhibitor Dolutegravir

Robert E. Ziegler, Bimbisar K. Desai, Jo-Ann Jee, B. Frank Gupton, Thomas D. Roper, and Timothy F. Jamison


May 2017

Increasing global access to the high-volume HIV drug nevirapine through process intensification

Jenson Verghese, Caleb J. Kong, Daniel Rivalti, Eric C. Yu, Rudy Krack, Jesus Alcázar, Julie B. Manley, D. Tyler McQuade, Saeed Ahmad, Katherine Belecki and B. Frank Gupton


May 2015

The Medicines for All Initiative: the nevirapine process optimization

Medicines for All


November 2015

The Medicines for All Initiative: continuous synthesis of nevirapine and reaction monitoring with online PAT

Medicines for All